List of Lonhala Magnair Kit drug patents

Lonhala Magnair Kit is owned by Sunovion Resp.

Lonhala Magnair Kit contains Glycopyrrolate.

Lonhala Magnair Kit has a total of 13 drug patents out of which 1 drug patent has expired.

Expired drug patents of Lonhala Magnair Kit are:

  • US7316067

Lonhala Magnair Kit was authorised for market use on 05 December, 2017.

Lonhala Magnair Kit is available in solution;inhalation dosage forms.

Lonhala Magnair Kit can be used as a method of using an aerosol delivery device to aerosolize glycopyrrolate for the treatment of chronic obstructive pulmonary disease (copd), long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).

The generics of Lonhala Magnair Kit are possible to be released after 07 December, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7316067 SUNOVION RESP Forming a perforate membrane by laser drilling and a subsequent electro-polishing step
Sep, 2022

(4 months ago)

US8511581 SUNOVION RESP Fluid droplet production apparatus and method
Nov, 2023

(9 months from now)

US7458372 SUNOVION RESP Inhalation therapy device
Nov, 2024

(1 year, 9 months from now)

US7931212 SUNOVION RESP Fluid droplet production apparatus and method
Nov, 2025

(2 years from now)

US11278683 SUNOVION RESP Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized
Aug, 2026

(3 years from now)

US9265900 SUNOVION RESP Disposable ampoule for an aerosol generating device
Dec, 2028

(5 years from now)

US10940110 SUNOVION RESP Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations
Feb, 2029

(6 years from now)

US9789270 SUNOVION RESP Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized
Oct, 2030

(7 years from now)

US9168556 SUNOVION RESP Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer
Sep, 2032

(9 years from now)

US9604018 SUNOVION RESP Aerosol therapy device
May, 2033

(10 years from now)

US10376661 SUNOVION RESP Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element
Sep, 2035

(12 years from now)

US10688518 SUNOVION RESP Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator
Nov, 2036

(13 years from now)

US10744277 SUNOVION RESP Aerosol delivery device and method of operating the aerosol delivery device
Dec, 2036

(13 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd); A method of using an aerosol delivery device to aerosolize glycopyrrolate for the treatment of chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION;INHALATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in